FloridaMarijuana.net

AUGUST 15, 2018

Evidence-based Complementary and Alternative Medicine published an article titled “Post-Traumatic Stress Disorder: Evidence-Based Research for the Third Millennium” which describes how profound the symptoms of PTSD can be: “Traumatic events are profoundly stressful. Women tend to experience different traumas than men.

Treatment 182

Treatment Marijuana Research and Development Therapy 182

The Joint Blog

APRIL 17, 2020

Over the past few decades, there has been an increased interest in leveraging cannabis and cannabinoids for medicinal purpose. But as an older user-base with more complicated medical conditions continue to grow, it is important to understand how THC could adversely impact other co-administered medications.

Events 48

Events THC Chronic Pain Sleep 48

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment. Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 105

Data Epilepsy Research and Development Clinical Trials 105

CannaMD

MAY 25, 2021

In recent years, research has revealed that two of marijuana’s two major cannabinoids — THC and CBD — can interact with the human endocannabinoid system to influence bone healing and regeneration. THC, CBD & THE ECS. In their summary, the study’s authors noted that. MARIJUANA AND OSTEOPOROSIS.

Marijuana 111

Marijuana Research and Development Clinical Trials THC 111

Veriheal

MAY 3, 2022

The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size. a necessary question to address as medical marijuana becomes more accessible. Daily Cannabis Use as a Disqualifier.

Research and Development 95

Research and Development Clinical Trials Consumption Patients 95

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

JANUARY 4, 2022

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’s Board of Directors, effective February 1 st , 2022. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

The Cannigma

MAY 19, 2021

Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 137

Law Legalization Clinical Trials CBD 137

Cannabis Law Report

JANUARY 6, 2022

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. In this position, Mr. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Otherside Farms

JANUARY 14, 2019

While there is a need for more clinical trials on the subject, users and alternative-therapy practitioners worldwide continue to buy cannabis seeds online for healing physical and mental ailments. It is at the root of many chronic health conditions, such as rheumatoid arthritis and atherosclerosis. Inflammation.

Clinical Trials 49

Clinical Trials Strains Therapy Medicine 49

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Since cannabinoids, including CBD, share metabolic pathways with other drugs, and have similar mechanisms of action with other drugs, the potential for interaction exists.

CBD 98

CBD THC Conditions Medicine 98

TheAnswerPage

JANUARY 11, 2022

and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ In addition, if clinicians are not well informed about the health effects of cannabinoid-based products, clinicians will not be able to optimally treat their patients. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

OCTOBER 19, 2021

Supera-CBD is MyMD’s pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 1, 2021

Supera-CBD is MyMD’s pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Since cannabinoids, including CBD, share metabolic pathways with other drugs, and have similar mechanisms of action with other drugs, the potential for interaction exists.

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

OCTOBER 15, 2021

Xebra’s strategy is to be the absolute first mover in cannabis in Mexico , in advance of formal legalization, by obtaining a Supreme Court injunction to legally commercialize hemp derived cannabinoids such as CBD and CBG. All statements, other than statements of historical facts, are forward-looking information and statements.

Seed-To-Sale 52

Seed-To-Sale Cultivation Clinical Trials Cannabinoids 52

Cannabis Law Report

SEPTEMBER 8, 2021

EPN’s facility is capable of product development, manufacturing, and commercialization of cannabis consumer packaged goods in addition to the manufacture of products and formulations for use in clinical trials to a TGA and EU GMP standard. The conditions precedent for the execution of the Definitive Agreements are: a. .

Access 97

Access Research and Development Medicine THC 97

Cannabis Law Report

NOVEMBER 12, 2021

Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP). Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Project CBD

MAY 3, 2023

Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

JANUARY 3, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid intoxication.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

NOVEMBER 12, 2021

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Project CBD

FEBRUARY 28, 2023

sativa do not naturally contain cannabinoids, but they can become contaminated with CBD from other plant parts during processing. 13 Although many review authors reported inconclusive findings due to low-quality studies, they noted that evidence from human clinical trials seems to support CBD’s positive effects on nociceptive pain (i.e.,

CBD 144

CBD Seed-To-Sale Food Access 144

The Joint Blog

JUNE 2, 2020

According to a new study published in the European Journal of Pain, delivering a precise doses of THC via a specialized inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions. Adverse events were mostly mild and resolved spontaneously.

Chronic Pain 58

Chronic Pain Clinical Trials Safety Marijuana 58

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Puff Puff Post

SEPTEMBER 16, 2019

This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. Clinical toolkits to help navigate patient assessment and follow-ups.

Programs 108

Programs Research and Development Education Treatment 108

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

NOVEMBER 1, 2021

The Company filed patent applications protecting its discovery of cannabinoid-based therapies where the A3AR target is overexpressed including liver cancer. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. About Can-Fite BioPharma Ltd. Can-Fite BioPharma.

Clinical Trials 52

Clinical Trials Research and Development Treatment Business 52

CannaMD

MARCH 8, 2020

Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease. a heart attack). More research is needed.

Patients 79

Patients Marijuana Research and Development Clinical Trials 79

Green Relief

MAY 13, 2018

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

THC 64

THC CBD Cannabinoids Research and Development 64

Puff Puff Post

SEPTEMBER 16, 2019

This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. Clinical toolkits to help navigate patient assessment and follow-ups.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. We also used manifest textual analysis to search for word frequencies, and specific conditions referred to in the articles retrieved. Medical publications, are, in the main fairly positive toward cannabis. Background.

Research and Development 52

Research and Development Medicine Access Media 52

Green Relief

MAY 12, 2018

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

NOVEMBER 7, 2019

With a strong focus on research and development ranging from agronomic research through to clinical trials Cannatrek has an extensive R&D portfolio from Seed to Patient. Cannatrek is actively working on clinical trial protocols with a dedicated focus on mental health.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40